Thousand Oaks Biopharmaceuticals, Inc. announced that it has received $45 million in its series A round of funding led by existing investor New Alliance Capital on January 2, 2019. The transaction also included participation from Broadhi Capital, Qianrong Capital, Jilin Aodong Medicine Industry Group Co., Ltd (SZSE:000623), Jiangsu Addor Equity Investment Fund Management Co., Ltd., Shenzhen Bluebay Equity Funds Partnership Enterprise (L.P.), and TenYall&Sumin Investment Management Co.